Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.

NCT03427866 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03427866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03427866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2018
Completion date
May 19, 2025
Enrollment
44 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis